Search

Your search keyword '"Yeh, K. -h."' showing total 212 results

Search Constraints

Start Over You searched for: Author "Yeh, K. -h." Remove constraint Author: "Yeh, K. -h."
212 results on '"Yeh, K. -h."'

Search Results

1. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

2. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

5. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

6. Results of the Photometric LSST Astronomical Time-series Classification Challenge (PLAsTiCC)

7. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice:: GLORIA-AF Registry

10. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

11. O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study

12. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

14. 558MO Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)

16. The contribution of Chinese process thought to psychology as a global science: Filial Piety as an example

18. 85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)

21. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

22. Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study

24. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

25. 246P The association of plasma soluble major histocompatibility complex class I polypeptide-related sequence A (sMICA) level with the pathological complete response (pCR) in locally advanced esophageal squamous cell carcinoma (ESCC)

26. Erratum to: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

28. 149PD Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI + cetuximab every other week in the APEC study

32. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

38. Differential response to H. pylori eradication therapy of co‐existing diffuse large B‐cell lymphoma and MALT lymphoma of stomach—significance of tumour cell clonality and BCL10 expression

Catalog

Books, media, physical & digital resources